Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin

Stopped Sponsor decided to stop commercialization of QTERNMet/Qtrilmet and to stop all related ongoing activities/studies for business reasons.

Conditions

• Type 2 Diabetes Mellitus

Interventions

• DRUG: Dapagliflozin 10 mg
• DRUG: Dapagliflozin 5 mg
• DRUG: Dapagliflozin 10 mg placebo to match
• DRUG: Dapagliflozin 5 mg placebo to match
• DRUG: Saxagliptin 5 mg
• DRUG: Metformin

Sponsor

AstraZeneca